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WU polyomavirus (WUPyV) was detected in 10 (8.3%) 
of 121 HIV-positive plasma specimens, 0 (0%) of 120 HIV-
negative serum specimens, and 2 (2.5%) of 79 hepatitis C 
virus  (HCV)–positive  serum  specimens.  KI  polyomavirus 
was not detected in HIV-positive plasma or HCV-positive 
serum specimens. HIV-infected persons may be suscep-
tible to systemic WUPyV infection.
I
n 2007, 2 new human polyomaviruses, KI polyomavirus 
(KIPyV) and WU polyomavirus (WUPyV), were identi-
fied. KIPyV was initially detected in an extract obtained 
from 20 pooled randomly selected nasopharyngeal aspi-
rates, and WUPyV was detected in a nasopharyngeal aspi-
rate from a 3-year-old child from Australia who had a di-
agnosis of pneumonia (1,2). These viruses have since been 
detected in respiratory tract specimens from symptomatic 
and asymptomatic children, although no clear association 
with respiratory disease has been demonstrated (3–6).
Previously identified human polyomaviruses (BK vi-
rus [BKV] and JC virus [JCV]) cause clinical disease in im-
munocompromised persons (7,8). Although viremia may 
be associated with immunosuppression, correlation of JCV 
DNA in peripheral blood with development of progressive 
multifocal encephalopathy in AIDS patients remains con-
troversial (9). BKV DNA has been detected in blood of re-
nal transplant patients, and BKV load may be predictive of 
polyomavirus-associated nephropathy (10).
The Study
The pathogenesis and clinical spectra of WUPyV and 
KIPyV,  particularly  in  immunocompromised  persons, 
have  not  been  defined.  To  investigate  whether  WUPyV 
or KIPyV is present in persons with chronic viral infec-
tion and perhaps compromised immunity, we conducted 
a cross-sectional study in which we screened the follow-
ing for WUPyV and KIPYV DNA: plasma samples from 
HIV-infected persons, serum samples from hepatitis C vi-
rus (HCV)–infected persons, and a control group of HIV-
negative persons.
Three groups of samples submitted to the Clinical Vi-
rology Laboratory at Yale–New Haven Hospital in 2007 
were  screened:  HIV  PCR-positive  plasma,  HCV  PCR-
positive serum, and HIV antibody-negative serum. Patient 
identifiers were removed and these specimens were tested 
as part of our ongoing investigation for newly identified 
viruses. Collection of specimens and clinical data was ap-
proved by the Yale University Human Investigation Com-
mittee and was compliant with Health Insurance Portability 
and Accountability Act regulations.
Nucleic acids were extracted from each specimen by 
using QIAamp nucleic acid purification kits (QIAGEN, Va-
lencia, CA, USA). Screening for WUPyV DNA has been 
described (6). Briefly, we performed an initial PCR screen-
ing specific for the virus capsid protein 2 (VP2) gene by us-
ing primers described by Gaynor et al. (2) and a nested PCR 
(Table 1, primers 1 and 2). To confirm results, DNA from 
all PCR-positive samples was reextracted and screened with 
primers specific for the region of the genome containing the 
noncoding control region (NCCR), which includes the virus 
origin of replication (genome coordinates 5213 to nt 36 of 
the circular viral genome). This screening included an initial 
PCR (Table 1, primers 3 and 4) and a nested PCR (Table 
1, primers 5 and 6). The nested PCR generated a 328-bp 
amplicon. Screening for KIPyV DNA by PCR included a 
nested PCR specific for the VP1 gene according to the pro-
tocol described by Allander et al. (1). Positive and negative 
controls were included in each set of PCRs.
All PCR products were sequenced by using 377 DNA 
automated sequencers (Applied Biosystems, Foster City, 
CA,  USA)  at  the  W.M.  Keck  Biotechnology  Resource 
Laboratory  at  Yale  University  School  of  Medicine.  For 
WUPyV, phylogenetic analysis was performed on a 194-
bp  fragment  within  the  amplified  region  of  NCCR  (nt 
5197 to nt 159 of the circular viral genome) by using La-
sergene  MegAlign  software  (DNASTAR  Inc.,  Madison, 
WI, USA) (ClustalW alignment method). The only clini-
cal data available for these deidentified serum specimens 
were HIV/HCV status and virus loads. HIV and HCV virus 
loads were determined in the Clinical Virology Laboratory 
by quantitative reverse transcription–PCR using commer-
cially available diagnostic tests. The Fisher exact test was 
used to determine whether the difference in the percentage 
of WUPyV-positive specimens in HIV-positive and HIV-
negative patients was statistically significant.
Ten (8.3%) of 121 HIV-positive specimens and 0 (0%) 
of 120 HIV-negative samples were positive for WUPyV 
(p<0.01) (Table 2). Two (2.5%) of 79 HCV-positive sam-
ples were positive for WUPyV. One of the 10 WUPyV-
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positive,  HIV-positive  specimens  was  also  positive  for 
HCV. Current HIV status for 2 of the WUPyV-positive, 
HCV-positive persons was not available. None of the HIV-
positive or HCV-positive specimens screened were posi-
tive for KIPyV (Table 2). HIV-negative specimens were 
not screened for KIPyV.
Mean HIV loads for WUPyV-positive and WUPyV-
negative,  HIV-positive  persons  were  32,200  copies/mL 
(range  2,930–88,300  copies/mL,  median  25,100  copies/
mL) and 131,500 copies/mL (range 509–750,000 copies/
mL, median 59,600 copies/mL), respectively. Mean HCV 
loads for WUV-positive and WUV-negative persons were 
1,302,200 copies/mL (range 88,600–3,906,600 copies/mL, 
median  1,909,000  copies/mL)  and  3,091,000  copies/mL 
(range  2,030–32,800,000  copies/mL,  median  1,150,000 
copies/mL), respectively.
Amplified  sequences  from  WUPyV-positive  serum 
specimens were compared with available sequences from 
GenBank  (all  of  which  were  obtained  from  respiratory 
specimens). Several nucleotide polymorphisms were ob-
served in the amplified portion of the NCCR of the New 
Haven WUPyV serum isolates (Figure). None of the nucle-
otide changes in the New Haven strains were mapped to the 
4 putative large T-antigen binding sites within the origin of 
replication (2).
Conclusions
We detected WUPyV in plasma specimens from HIV-
infected persons and in serum specimens from HCV-infect-
ed persons in Connecticut in 2007. Detection of WUPyV 
indicates that this newly identified polyomavirus is pres-
ent in peripheral blood of HIV-positive or HCV-positive 
persons. It does not appear that WUPyV viremia corre-
lates with HIV or HCV virus load. We did not assess the 
WUPyV serologic status of these persons. However, if the 
seroepidemiology of WUPyV is similar to that of BKV 
and JCV, we predict that >85% of the persons screened 
will have detectable antibodies to WUPyV (11). Whether 
antibody status for WUPyV correlates with viremia is un-
known. Viremia may represent primary infection or reacti-
vation of latent infection.
Viremia has been described for JCV and BKV. JCV 
DNA in serum/plasma may correlate with the degree of im-
munosuppression.  However,  blood  from  viremic  persons 
infected with JCV has a low positive predictive value for 
development of progressive multifocal encephalopathy in 
AIDS patients (9). A recent study suggested that screening 
for BKV replication is useful in identifying patients at risk 
for BKV-associated nephropathy, which may enable early 
interventions such as renal biopsy and reduction of immu-
nosuppression (12). However, because of the lack of clini-
cal data available for WUPyV-positive persons in our study, 
it was not possible to make any clinical correlations.
The absence of KIPyV in HIV-positive or HCV-posi-
tive peripheral blood specimens suggests that host suscep-
tibility for KIPyV may differ from that of WUPyV, as for 
JCV and BKV. However, this hypothesis was not support-
ed by a recent study that reported KIPyV and WUPyV in 
autopsy lymphoid tissues of AIDS patients (13). Whether 
WUPyV or KIPyV cause disease in HIV-positive persons 
or other populations remains to be determined.
Our data demonstrate that WUPyV was detected in pe-
ripheral blood of HIV- and HCV-infected persons. Howev-
er, the scope of this study was limited because clinical data 
were not available for study participants. Whether WUPyV 
or KIPyV have oncogenicity or other pathogenicity in im-
munocompromised hosts remain to be determined. The role 
of polyomaviruses in human cancers has been extensively 
investigated but conclusive evidence is lacking (14). The 
genome of Merkel cell polyomavirus, a new polyomavi-
rus, was found to be integrated within the cellular genome 
of Merkel cell carcinoma tissue samples, which suggests a 
role for this virus in a specific tumor (15). Therefore, stud-
ies to assess the oncogenic potential of WUPyV and KIPyV 
are also needed.
Table 1. Primers used in PCR to detect WU polyomavirus in serum specimens, Connecticut, USA, 2007 
Primer  Name  Sequence (5ƍ ĺ 3ƍ)  Genome coordinates 
1  WU2F*
  GCGCATCAAGAGGCACAGCTACTATTTC  1377–1400 
2  WU2R*
  GCGCCTAGCCTGTGAACTCCATC  1510–1528 
3  WUoriFnest†
  CTCATTTCCCCCTTTGTCAGGATG  5011–5034
 
4  WUoriRII†
  CTTTCCGCTGGACTACAAAGGGC  317–339
 
5  WUoriF†
  GTAAATTTCCCCAGCAGGTC  5075–5095
 
6  WUoriR†
  CGGAAACTTTAAAAGGTCACAG  153–174
 
*Primers used by Wattier et al. (6). 
†The amplicon generated with these primer spans across nt 1 of the 5,229-bp circular virus genome. 
Table 2. Detection of WU and KI polyomaviruses in HIV-positive 
plasma, HIV-negative serum, and HCV-positive serum 
specimens, Connecticut, USA, 2007* 
Specimen
group
No. WU virus–positive 
specimens/total no. 
specimens tested (%) 
No. KI virus–positive 
specimens/total no. 
specimens tested (%) 
HIV+ 10/121 (8.3)†  0/120
HIV– 0/120 (0)  Not tested 
HCV+ 2/79 (2.5)  0/80
*HCV, hepatitis C virus. 
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Figure. Nucleotide polymorphisms in the noncoding region of WU 
polyomavirus  (WUPyV),  Connecticut,  USA,  2007.  Sequences 
spanning nt 5197 to 159 of the circular viral genome of New Haven 
human serum isolates and all available sequences from GenBank 
(all from respiratory specimens) were subjected to phylogenetic 
analysis. A map of the noncoding region within the viral genome 
is indicated at the top of the figure (not to scale). The arbitrary 
last  (5229)  and  first  (1)  nucleotide  of  the  circular  viral  genome 
are indicated. The putative large T antigen (TAg) binding sites for 
each strand of the double-strand genome are indicated by black 
boxes, and the A/T-rich region is indicated by a gray box. Position 
of nucleotide polymorphism is indicated below the map. Strains 
(location and GenBank accession nos.) are listed in order according 
to phylogenic analysis. The consensus sequence is listed first, and 
polymorphisms are indicated by boxes. The strain indicated by the 
black arrow is a WUPyV New Haven respiratory isolate (6), and the 
strain indicated by the white arrow is the original WUPyV isolate 
(2). VP2, virus capsid protein 2.
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